Prospective multicenter study of ctDNA versus tumor tissue guiding FGFR-targeted therapy in metastatic urothelial cancer - PubMed
3 hours ago
- #metastatic urothelial cancer
- #ctDNA
- #FGFR-targeted therapy
- Prospective multicenter study compares ctDNA and tumor tissue for guiding FGFR-targeted therapy in metastatic urothelial cancer (mUC).
- FGFR alterations are targetable in mUC, but current tissue testing is limited by sample availability and tumor heterogeneity.
- Plasma ctDNA testing shows high concordance with tissue FGFR testing and identifies additional actionable FGFR alterations.
- Among 208 patients, FGFR alteration frequency was 26% in either tissue or ctDNA, with 90% concordance in paired samples.
- ctDNA testing had 84% sensitivity for tissue-detected alterations and identified 7 additional cases with FGFR alterations.
- Serial plasma collections post-baseline helped further clarify FGFR status in patients.
- Patients treated with erdafitinib had a median progression-free survival of 7.5 months, with one patient remaining on treatment for 33 months.
- The study supports the clinical use of ctDNA FGFR testing alongside tissue-based approaches in mUC.